Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia

In a randomized multicenter study, ciprofloxacin and norfloxacin, each in two different dose regimens and in combination with non-absorbable antimycotics, were administered to 51 patients with acute leukaemia undergoing aggressive remission induction chemotherapy for infection prevention. Both drugs...

Full description

Saved in:
Bibliographic Details
Published in:Infection 1988-03, Vol.16 (2), p.98-104
Main Authors: MASCHMEYER, G, HARALAMBIE, E, GAUS, W, KERN, W, DEKKER, A. W, DE VRIES-HOSPERS, H. G, SIZOO, W, KÖNIG, W, GUTZLER, F, DAENEN, S
Format: Article
Language:English
Subjects:
Acute Disease
Adult
Agranulocytosis - chemically induced
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Bacterial Infections - prevention & control
Biological and medical sciences
Ciprofloxacin - administration & dosage
Ciprofloxacin - therapeutic use
Clinical Trials as Topic
Humans
Leukemia - drug therapy
Medical sciences
Norfloxacin - administration & dosage
Norfloxacin - therapeutic use
Pharmacology. Drug treatments
Pilot Projects
Random Allocation
Remission Induction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a randomized multicenter study, ciprofloxacin and norfloxacin, each in two different dose regimens and in combination with non-absorbable antimycotics, were administered to 51 patients with acute leukaemia undergoing aggressive remission induction chemotherapy for infection prevention. Both drugs showed an effective elimination of gram-negative potential pathogens and Staphylococcus aureus not affecting the anaerobic flora of the gastrointestinal tract. A low incidence of side effects and a satisfactory patient compliance could be observed. A daily dosage of 1,000 mg ciprofloxacin or 800 mg norfloxacin is recommended for infection prevention in severely granulocytopenic patients.
ISSN:0300-8126
1439-0973
DOI:10.1007/BF01644312